Metastatic Castrate-sensitive Prostate Cancer

Oncology

Prevalence

256.0 / 100K

Incidence

111.0 / 100K/yr

4 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

Frequently asked questions

How many drugs are in development for Metastatic Castrate-sensitive Prostate Cancer?

BioSniper tracks 4 drugs in development for Metastatic Castrate-sensitive Prostate Cancer across 4 companies.

How many clinical trials target Metastatic Castrate-sensitive Prostate Cancer?

There are 1 clinical trial targeting Metastatic Castrate-sensitive Prostate Cancer tracked by BioSniper.

What is the prevalence of Metastatic Castrate-sensitive Prostate Cancer?

The estimated prevalence of Metastatic Castrate-sensitive Prostate Cancer is approximately 256.0 per 100,000 population.

Deep-dive into Metastatic Castrate-sensitive Prostate Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Metastatic Castrate-sensitive Prostate Cancer — Drugs in Development & Clinical Trials | BioSniper